A whistleblower alleged that Bristol-Myers Squibb misreported prices on more than 200 drug products, reducing Medicaid rebates it owed to states.

340B Entities Won’t Share in BMS’s $75 Million Medicaid Drug Pricing Settlement

340B covered entities were not included in Bristol-Myers Squibb’s $75 million settlement last week of a whistleblower’s claims that BMS “falsely reported improperly reduced average manufacturer prices” (AMPs) on multiple drugs from October 2007 through March 2016.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »